WELL Health Strengthens Executive Leadership Team with Appointments of Loreto Grimaldi as Chief Legal Officer and Kaytek Przybylski as Chief Digital & Information Officer
WELL appoints accomplished legal and business executive Loreto Grimaldi as Chief Legal Officer to lead legal, compliance, governance, risk management and M&A activities across the organization. Seasoned technology and digital transformation leader Kaytek Przybylski joins WELL as Chief Digital & Information Officer to lead enterprise technology, digital transformation, data, AI, and cybersecurity and technology shared services strategy.
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-08-04 6:30 AM EDT | WELL Health Technologies Corp.
WELL Health to Announce Second Quarter 2026 Financial Results on August 6, 2026
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that the Company will release its Fiscal Second Quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursd
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-08-04 6:00 AM EDT | WELL Health Technologies Corp.
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2026) - As the global healthcare community unites on August 1st to observe World Lung Cancer Day, BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company") proudly aligns with leading international healthcare organizations demanding equal access to early detection by developing simple, accessible blood testing that empowers patients and physicians with critical diagnostic insights when it matter
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-07-31 8:30 AM EDT | BioMark Diagnostics, Inc.
WELL Health Subsidiary WELLSTAR Closes C$50 Million Financing Transaction Ahead of Planned TSXV Listing
Vancouver, British Columbia--(Newsfile Corp. - July 31, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ("WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that its subsidiary, WELLSTAR Technologies Corp. ("WELLSTAR"), has closed a financing transaction for aggregate gross proceeds of C$50 million (the "Financing
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-07-31 8:17 AM EDT | WELL Health Technologies Corp.
Jack Nathan Medical Corp. Announces Board Changes and Corporate Update
Toronto, Ontario--(Newsfile Corp. - July 31, 2026) - Jack Nathan Medical Corp. (TSXV: JNH) (OTC Pink: JNHMF) ("Jack Nathan" or the "Company") announces that Blake Lyon, Chairman of the Board of Directors, and Anthony DeCristofaro, Director, have resigned from the Board of Directors of the Company (the "Board"), effective July 31, 2026. Mr. Lyon and Mr. DeCristofaro have each served the Company for many years and have contributed significant time, leadership and experience throughout the
Soins de santé et hôpitaux, Commerce de détail, Santé
2026-07-31 6:00 AM EDT | Jack Nathan Medical Corp.
Medexus Schedules First Fiscal Quarter 2027 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Tuesday, August 11, 2026 to discuss Medexus's results for its first fiscal quarter ended June 30, 2026. Medexus expects to file its financial statements and MD&A after markets close on August 10, 2026. To participate in the call, please dial the following numbers:
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-30 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Richards Group Inc. Announces 2026 Second Quarter Results: Revenue Growth of 5% Primarily on Acquisitions; Gross Margins up 18%
Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today results for the quarter ended June 30, 2026. Second Quarter 2026 Highlights: Revenue contributions from acquisitions including DermapenWorld (June 2025) and PharmaSystems (May 2026) drove overall increase of 5.2%. Organic Healthcare revenue up 7.3%, representing a solid q
Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques, Pharmaceutique
2026-07-30 5:00 PM EDT | Richards Group Inc.
NewOrg Management System to Launch Its Biggest Update Ever, Reshaping How Nonprofits Manage Data
Washington, D.C.--(Newsfile Corp. - July 30, 2026) - NewOrg Management System, a cloud-based data and case management platform built for nonprofits, human services organizations, and government programs across the United States and Canada, today announced the largest platform update in the company's history. Beginning August 1, 2026, eight new capabilities will roll out across the platform, spanning artificial intelligence, security, and day-to-day operations. The update includes new AI
Logiciels, Soins de santé et hôpitaux, Logement, Autochtones
2026-07-30 12:00 PM EDT | NewOrg Management System Inc
Bachem Confirms Growth and Expects a Strong Second Half 2026
Bubendorf, Switzerland--(Newsfile Corp. - July 30, 2026) - Ad hoc announcement pursuant to Art. 53 LR Media Release Group sales grew to CHF 326.4 million (+4.3% compared to the prior-year period, +7.3% in local currencies). EBITDA amounted to CHF 82.8 million (-9.0% compared to the prior-year period, -4.2% in local currencies) with a margin of 25.4% (prior-year period: 29.1%).
Biotechnologies, Produits chimiques, Soins de santé et hôpitaux, Pharmaceutique
2026-07-30 12:56 AM EDT | Bachem Holding AG
CareRx Announces Q3 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today announced that the Company's Board of Directors has declared a dividend of CAD$0.022 per outstanding common share of the Company ("Common Shares"), payable on October 8, 2026, to holders of record of Common Shares as of the close of business on Septembe
2026-07-29 6:20 PM EDT | CareRx Corporation
CareRx Reports Results for the Second Quarter of 2026
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company"), Canada's leading provider of pharmacy services to seniors living and other congregate care communities, today reported its financial results for the second quarter ended June 30, 2026. Highlights for the Second Quarter of 2026 Average Beds Serviced1 increased to 91,719 in Q2 2026 from 90,048 Averag
2026-07-29 6:20 PM EDT | CareRx Corporation
Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical Study
Winter Park, Florida--(Newsfile Corp. - July 29, 2026) - Adia Med Inc. (OTCQB: ADIA) today announced two distinct milestones in its Autism Spectrum Disorder (ASD) clinical research study (ClinicalTrials.gov Identifier: NCT07304440): the completion of Phase 1 treatment for the study's first cohort of children, and the formal launch of Phase 2 of the study. Separately, the company confirmed that a new cohort of 30 children will begin its own Phase 1 treatment on October 1, 2026, as part of the
Soins de santé et hôpitaux, Santé
2026-07-29 6:00 AM EDT | Adia Med Inc.
Launchit Solutions and Privacy Horizon Partner to Help Canadian Health Tech Companies Build, Govern, and Scale with Confidence
Toronto, Ontario--(Newsfile Corp. - July 28, 2026) - Launchit Solutions and Privacy Horizon today announced a strategic partnership that gives Canadian health tech startups and scale-ups coordinated access to healthcare software development, Canadian cloud infrastructure, data governance, privacy and security readiness, and responsible AI governance. Bringing together more than 40 years of combined experience across healthcare, technology, privacy, cybersecurity, and governance, the partnersh
Technologies, Logiciels, Soins de santé et hôpitaux
2026-07-28 10:00 AM EDT | Launchit Solutions Inc.
NuGen Adds to Core Patent Portfolio for Future Needle-Free Platforms
Toronto, Ontario--(Newsfile Corp. - July 27, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free drug delivery, today announced the filing of two additional patent applications supporting its current patent portfolio. The new applications focus on high-efficiency spring charging technology and automatic dose-establishment technology. Together with previously announced patent applications relating to the Company's dual-spring
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-27 5:15 PM EDT | NuGen Medical Devices Inc.
TelyRx to Host Second Quarter 2026 Financial Results Conference Call on Monday, August 10, 2026 at 8:30 am ET
Clearwater, Florida--(Newsfile Corp. - July 24, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced it will host a conference call and webcast to discuss its second quarter 2026 financial results on Monday, August 10, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its second quarter 2026 financial results for the period ended
Soins de santé et hôpitaux, Santé
2026-07-24 7:35 AM EDT | TelyRx
LDIC Inc. Announces the Termination of the Healthcare Special Opportunities Fund
Toronto, Ontario--(Newsfile Corp. - July 23, 2026) - LDIC Inc. (TSX: MDS.UN) (the "Manager") today announced that it will pursue the termination of the Healthcare Special Opportunities Fund (the "Fund") to be effected in the third quarter of 2026 (the "Termination"), subject to obtaining the necessary approvals from the unitholders and regulatory authorities. The Manager has reviewed the current size of the Fund, its management expense ratio, its po
Services bancaires / financiers, Soins de santé et hôpitaux
2026-07-23 5:01 PM EDT | Healthcare Special Opportunities Fund
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
Ad hoc announcement pursuant to Art. 53 LR Recurring revenues from Winlevi® up 38%, Lialda® up 35%, and CDMO up 14% year-over-year Clascoterone Phase III 12-month data support chronic use, with regulatory submissions underway in the US and in Europe Debt-free with more than €205 million in cash, cash equivalents and investments
Soins de santé et hôpitaux, Santé
2026-07-23 1:01 AM EDT | Cosmo Pharmaceuticals N.V.
medmix Strengthens Profitability and Cash Flow While Advancing Growth and Efficiency Initiatives
Baar, Switzerland--(Newsfile Corp. - July 23, 2026) - Ad hoc announcement pursuant to Art. 53 LR MEDIA RELEASE Ad hoc announcement pursuant to Art. 53 LR Half-Year 2026 Results
Technologies, Construction / bâtiments, Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques
2026-07-23 12:09 AM EDT | medmix AG
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-22 12:30 PM EDT | Phio Pharmaceuticals Corp.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Canada
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - July 22, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that Vitalité Health Network has joined as the first Canadian site in its large multi-center observational data collection study to advance the development of its t
Technologies, Biotechnologies, Soins de santé et hôpitaux, Santé
2026-07-22 10:00 AM EDT | Breathe BioMedical Inc.